Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Akebia Therapeutics's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Akebia Therapeutics was 15.33. The lowest was 3.68. And the median was 9.29.
FRA:AX9's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.69 * Ranked among companies with meaningful Price-to-Net-Cash only.
Akebia Therapeutics (FRA:AX9) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Akebia Therapeutics Net Cash per Share Related Terms
Akebia Therapeutics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AX9 vs ORGO, EBS, TKNO: Net Cash per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Price-to-Net-Cash falls into.
Akebia Therapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Akebia Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (FRA:AX9) has a Net Cash per Share of €-0.54 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Akebia Therapeutics and its competitors. Over the past decade, Akebia Therapeutics' Net Cash per Share has ranged from 3.68 to 15.33. According to the industry distribution chart, Akebia Therapeutics ranks #999999 out of 247 companies in the Drug Manufacturers industry.
Is Akebia Therapeutics' Net Cash per Share too high?
Akebia Therapeutics' current Net Cash per Share is €-0.54. Over the past 10 years, this metric has ranged from a low of 3.68 to a high of 15.33. Based on the distribution chart, Akebia Therapeutics ranks #999999 out of 247 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Akebia Therapeutics has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Net Cash per Share compare to ORGO and EBS?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #999999 out of 247 companies for Net Cash per Share. This places Akebia Therapeutics in the lower half of its industry. The industry median Net Cash per Share is 8.69. Historically, Akebia Therapeutics' own Net Cash per Share has ranged from 3.68 to 15.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.69, based on 247 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current Net Cash per Share is €-0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.99, compared to a current price of €0.74 — trading 25.3% below its estimated fair value. The current Net Cash per Share is €-0.54. Akebia Therapeutics' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current Net Cash per Share is €-0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €0.74 is trading 25.3% below its estimated GF Value™ of €0.99.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for FRA:AX9:
Net Cash per Share: €-0.54
GF Value™: €0.99 vs. price of €0.74 (25.3% below fair value)
No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
47GF Score
Get the complete analysis for FRA:AX9
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX9 has been successfully added to your 
